Tecvayli (teclistamab-cqyv)
Named-patient access overview. Tecvayli is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Tecvayli
Tecvayli (teclistamab-cqyv) is a BCMA x CD3 bispecific T-cell engager developed by Janssen Biotech (a Johnson and Johnson company) in collaboration with Genmab. By simultaneously binding B-cell maturation antigen (BCMA) on myeloma cells and CD3 on cytotoxic T cells, it brings the patient's own T cells into direct contact with the tumour to drive immune-mediated killing.
Tecvayli received accelerated FDA approval in October 2022 for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is administered as a subcutaneous (SC) injection and requires a step-up dosing regimen during initiation to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Because of the boxed warnings for CRS and neurologic toxicity, initiation and step-up doses must be administered in a setting equipped for inpatient observation and rapid intervention. Tecvayli is distributed in the US under a Risk Evaluation and Mitigation Strategy (REMS) programme. International access via Named Patient Program or personal-import pathways is coordinated by Reserve Meds for patients in markets where Tecvayli is not yet locally registered.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Tecvayli
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Tecvayli for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Tecvayli is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Tecvayli in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Tecvayli
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Reserve Meds coordinates Tecvayli through Johnson and Johnson portfolio overview for the full cross-border catalog.